site stats

Jounce stock price

NettetShareholders have faith in loss-making Jounce Therapeutics (NASDAQ:JNCE) as stock climbs 12% in past week, taking three-year gain to 95% Simply Wall St. Nov-04-21 … NettetJounce Therapeutics Driven by Science. Motivated by Patients. about About Jounce Management Board of Directors Company Founders our approach Focus on Patients …

JNCE Jounce Therapeutics Inc. Stock Price & News - WSJ

NettetJounce Therapeutics Inc (JNCE) NASDAQ Add to Watchlist 1.890 -0.010 ( -0.53 %) 06/04 - Closed. Currency in USD ( Disclaimer) After Hours 1.890 0.000 ( 0.00 %) 06/04 - Real-time Data Volume:... NettetJounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T ... hiksink https://baileylicensing.com

JNCE Price Target 2024 Jounce Therapeutics Analyst Ratings

Nettet15. mar. 2024 · View the latest Jounce Therapeutics Inc. (JNCE) stock price, news, historical charts, analyst ratings and financial information from WSJ. JNCE Jounce … NettetUse our historic performance chart to see real-time Jounce Therapeutics Inc stock price and the Jounce Therapeutics Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose. 2. Choose a Stash plan and set up your investment account in just a few minutes. Nettet12. apr. 2024 · According to the issued ratings of 5 analysts in the last year, the consensus rating for Jounce Therapeutics stock is Hold based on the current 4 hold ratings and 1 … hiksimi

Jounce Therapeutics (JNCE) Stock Forecast & Price Prediction …

Category:Jounce Therapeutics Stock Price Today (NASDAQ: JNCE) Quote, …

Tags:Jounce stock price

Jounce stock price

Jounce Therapeutics - JNCE Stock Forecast, Price & News - MarketBeat

NettetJounce Therapeutics Inc (JNCE) Stock Price Today, News, Quotes, FAQs and Fundamentals More Advertisement 3rd Party Ad. Not an offer or recommendation by … NettetJNCE: Get the latest Jounce Therapeutics stock price and detailed information including JNCE news, ... According to the current price, Jounce Therapeutics is 23.05% away from the 52-week high.

Jounce stock price

Did you know?

Nettet4. apr. 2024 · JOUNCE THERAPEUTICS, INC. : JNCE Stock Price US4811161011 MarketScreener Homepage Equities United States Nasdaq Jounce Therapeutics, Inc. … Nettet10. apr. 2024 · Jounce Therapeutics NasdaqGS:JNCE Stock Report Last Price US$1.85 Market Cap US$96.8m 7D 22.5% 1Y -74.1% Updated 02 Apr, 2024 Data Company …

NettetJounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma. CRSP : 45.40 (+1.34%) JNCE : 1.8900 (-0.53%) CERT : 23.01 (+0.52%) EQRX : 1.8900 (+2.72%) SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, USX, JNCE … Nettet31. mar. 2024 · March 14, 2024. 9:00 pm ET. Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences. Globe Newswire. March 13, 2024. 7:00 am ET. Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account. MarketWatch. March 09, 2024.

Nettet13. apr. 2024 · Jounce Therapeutics Inc. (NASDAQ:JNCE) shares, rose in value on Wednesday, 04/12/23, with the stock price up by 1.07% to the previous day’s close as strong demand from buyers drove the stock to $1.89. Actively observing the price movement in the last trading, the stock closed the session at $1.87, falling within a … NettetJounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 27, 2024TipRanks. …

Nettet31. mar. 2024 · nasdaq.com - October 17 at 3:31 PM. Jounce Therapeutics to Participate in the Upcoming Investor Conferences. finance.yahoo.com - September 7 at 9:45 AM. Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down. nasdaq.com - August 31 at 12:04 PM. Jounce Therapeutics Shares Fall After Disappointing Mid-Stage Lung …

Nettet27. mar. 2024 · JOUNCE THERAPEUTICS, INC. (Name of Person (s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number of Common Stock) Jacquelyn... hiksolutionNettet14. apr. 2024 · Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, Jounce Therapeutics presently has an average rating of "Hold" and a consensus target price of $6.00. Jounce Therapeutics Price Performance. Shares of NASDAQ:JNCE opened at … hiksaiNettet7. mar. 2024 · Jounce Therapeutics Inc. (NASDAQ:JNCE) traded at $1.06 at last check on Tuesday, March 07, made a downward move of -1.85% on its previous day’s price. Looking at the stock we see that its previous close was $1.08 and the beta (5Y monthly) reads 0.65 with the day’s price range being $1.01 hiksa porcelainNettet5. apr. 2024 · Jounce Therapeutics (JNCE) Stock Price & Analysis 302 Followers JNCE Stock Chart & Stats Advanced Chart > Day’s Range $0 - $0 52-Week Range $0.58 - $7.94 Previous Close $1.85 Volume 5.37M Average Volume (3M) 2.75M Market Cap $96.46M Enterprise Value $96.46M Total Cash (Recent Filing) $0.00 Total Debt (Recent Filing) … hikuazn settingsNettet18. apr. 2024 · According to our current JNCE stock forecast, the value of Jounce Therapeutics, Inc. shares will rise by 5.41%and reach $ 3.68 per share by September 14, 2024. According to our technical indicators, the current sentiment is Bearishwhile the Fear & Greed Index is showing 39 (Fear). hiks hitta kliniska studierNettetJNCE: Get the latest Jounce Therapeutics stock price and detailed information including JNCE news, ... According to the current price, Jounce Therapeutics is 23.05% away … hiksionNettet29. des. 2024 · Jounce’s cash position at the end of September 2024 was $130.3 million compared to $220.2 million as of December 31, 2024. That means its cash burn is quite high, with approximately $120 million... hikuillui